Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects With MET+ Advanced Hepatocellular Carcinoma With Child Pugh Class A Liver Function Who Have Failed Sorafenib Treatment

Next Previous
Search
Trial Profile

A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects With MET+ Advanced Hepatocellular Carcinoma With Child Pugh Class A Liver Function Who Have Failed Sorafenib Treatment

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tepotinib (Primary)
  • Indications Carcinoma; Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck KGaA

    • Most Recent Events

    • 01 Jul 2022 Results of a pooled exposure-efficacy analyses included data from an ongoing phase 2 study (VISION) and 4 completed studies (NCT01014936, NCT01832506, NCT01988493, NCT02115373, NCT02864992) investigating 500 mg/day tepotinib in NSCLC harboring METex14 skipping alterations published in the Cancer Chemotherapy and Pharmacology
    • 06 Apr 2021 Results published in the British Journal of Cancer
    • 17 Jan 2021 Results from NCT01988493 and NCT02115373 assesing activity of tepotinib in hepatocellular carcinoma with high level MET amplification, presented at the 2021 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top